Bevacizumab for Retinopathy of Prematurity

The use of anti–vascular endothelial growth factor (anti-VEGF) agents has revolutionized the treatment of certain neovascular ocular conditions including age-related macular degeneration. Off-label use of bevacizumab increased rapidly because it was readily available, inexpensive, and offered positive clinical results in patients with a major disease (age-related macular degeneration) for which there were no other good treatment options. In this issue of the Journal, Mintz-Hittner and colleagues1 describe a multicenter, randomized trial with the potential to stimulate a dramatic shift in the treatment of acute retinopathy of prematurity.Retinopathy of prematurity is a disease of the immature retina in which preterm . . .